




[FIG. 1a]



[FIG. 1b]




[FIG. 2]




	Low (DI ≤20) (N=269, 65.1%)	High (DI >20) (N=144, 34.9%)
Distant Metastasis (N)	20 (7.4%)	57 (39.6%)
5-year Metastasis-free Survival	97.03 % (94.14, 98.50)	77.08 % (69.32, 83.12)
10-year Metastasis-free Survival	92.63 % (88.25, 95.42)	61.62 % (52.22, 69.71)
Log-rank (p-value)	<0.0001	
Hazard Ratio (p-value)	6.568 (3.938, 10.956); <0.0001	

[FIG. 3a]



Age ≤ 50	Low (DI ≤ 20) (N=176, 67.7%)	High (DI > 20) (N=84, 32.3%)
Distant Metastasis (N)	11 (6.3%)	32 (38.1%)
5-year Metastasis-free Survival	97.73 % (94.06, 99.14)	78.57% (68.17, 85.92)
10-year Metastasis-free Survival	93.60 % (87.96, 96.83)	58.96 % (45.46, 70.18)
Log-rank (p-value)	<0.0001	
Hazard Ratio (p-value)	7.794 (3.919, 15.502) (<0.0001)	

[FIG. 3b]



Age > 50	Low (DI ≤20) (N=93, 60.8%)	High (DI >20) (N=60, 39.2%)
Distant Metastasis (N)	9 (9.7%)	25 (41.7%)
5-year Metastasis-free Survival	95.70 % (88.95, 98.36)	75.00 % (62.00, 84.10)
10-year Metastasis-free Survival	89.98 % (80.77, 94.92)	64.06 % (50.28, 74.95)
Log-rank (p-value)	<0.0001	
Hazard Ratio (p-value)	5.114 (2.379, 10.994) (<0.0001)	